Acticor Makes Case For First-In-Class Heart Drug Glencozimab
French Biotech Initiates Phase II/III Trials
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.
You may also be interested in...
UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
Egetis Ends Takeover Talks To Focus On Emcitate
The Swedish firm has decided to pass on a bid from a proposed buyer which would have involved a healthy premium but “considerably undervalued” its long-term prospects.
BenevolentAI Slashes Jobs And Drug Programs
The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.